home / stock / aqst / aqst articles


AQST Articles, Aquestive Therapeutics Inc. - From 03/20/24

Stock Information

Company Name: Aquestive Therapeutics Inc.
Stock Symbol: AQST
Market: NASDAQ
Website: aquestive.com

Menu

AQST AQST Quote AQST Short AQST News AQST Articles AQST Message Board
Get AQST Alerts

News, Short Squeeze, Breakout and More Instantly...

Why Taysha Gene Therapies Shares Are Trading Higher By Around 27%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose sharply in today’s pre-market trading after the company reported a year-over-year ...

Harrow Posts Weak Q4 Results, Joins TeraWulf, Nasdaq And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session | Benzinga

U.S. stock futures were slightly lower this morning, with the Dow futures falling by around 0.1% on Wednesday. Shares of Harrow, Inc. (NASDAQ: HR...

Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock | Benzinga

WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical com...

Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Benzinga

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued...

Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-...

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session | Benzinga

Shares of Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial r...

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update | Benzinga

Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 million Reaffirms expected release of topline pivotal ...

Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference | Benzinga

WARREN, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to brin...

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting | Benzinga

WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical comp...

Aquestive Therapeutics Completes $45 Million Debt Refinancing | Benzinga

WARREN, N.J., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to brin...

Previous 10 Next 10